U.S. patent number 3,882,245 [Application Number 05/418,501] was granted by the patent office on 1975-05-06 for use of prostaglandins in combating shock.
This patent grant is currently assigned to The Upjohn Company. Invention is credited to Donald W. Du Charme.
United States Patent |
3,882,245 |
Du Charme |
May 6, 1975 |
Use of prostaglandins in combating shock
Abstract
A process of treatment for the clinical management of the
condition known as shock in which acute peripheral circulatory
failure occurs, usually because of injury. The process clinically
manages shock by parenteral administration to mammals, for example
humans and valuable warm-blooded domestic animals such as dogs and
cats suffering from shock a sufficient amount of certain
prostaglandins for combating the acute peripheral circulatory
failure. The process utilizes a prostaglandin or prostaglandins
alone or in conjunction with other medication known to be
beneficial in shock.
Inventors: |
Du Charme; Donald W.
(Kalamazoo, MI) |
Assignee: |
The Upjohn Company (Kalamazoo,
MI)
|
Family
ID: |
26973071 |
Appl.
No.: |
05/418,501 |
Filed: |
November 23, 1973 |
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
302714 |
Nov 1, 1972 |
|
|
|
|
159561 |
Jul 2, 1971 |
|
|
|
|
884017 |
Dec 10, 1969 |
|
|
|
|
622029 |
Mar 10, 1967 |
|
|
|
|
Current U.S.
Class: |
514/559 |
Current CPC
Class: |
A61K
31/54 (20130101); A61K 31/415 (20130101); A61K
31/57 (20130101); A61K 31/557 (20130101); A61K
31/415 (20130101); A61K 31/20 (20130101); A61K
31/54 (20130101); A61K 31/20 (20130101); A61K
31/57 (20130101); A61K 31/20 (20130101); A61K
31/20 (20130101); A61K 31/135 (20130101) |
Current International
Class: |
A61K
31/415 (20060101); A61K 31/54 (20060101); A61K
31/57 (20060101); A61K 31/557 (20060101); A61k
027/00 () |
Field of
Search: |
;424/318,305 |
References Cited
[Referenced By]
U.S. Patent Documents
Other References
Callingham - The Pharmaceutical Journal, Apr. 25, 1970, pages
433-436. .
Chem. Abst., Vol. 69 (1968) page 103476p. .
Clegg, Nature - Vol. 209, No. 5028, Mar. 12, 1966, pages
1,137-1,139..
|
Primary Examiner: Rosen; Sam
Parent Case Text
This is a continuation of copending application Serial No. 302,714,
filed Nov. 1, 1972, now abandoned, which is a continuation of
copending application Ser. No. 159,561, filed July 2, 1971, now
abandoned, which is a continuation-in-part of copending application
Ser. No. 884,017, filed Dec. 10, 1969, now abandoned, which is a
continuation-in-part of copending application Ser. No. 622,029,
filed Mar. 10, 1967, now abandoned.
Claims
I claim:
1. A method of combating shock which consists essentially of
administering parenterally to a mammal in shock a pharmaceutical
form supplying a nontoxic effective amount of a prostaglandin
selected from the group consisting of an A-type prostaglandin, and
E-type prostaglandin, an F-type prostaglandin, and pharmaceutically
acceptable salts thereof.
2. The method of claim 1 which includes concommitant parenteral
administration of a member selected from the group consisting of
norepinephrine, dopamine, phenoxybenzamine hydrochloride,
phentolamine hydrochloride, chlorpromazine hydrochloride,
promethazine hydrochloride, hydrocortisone sodium succinate,
methylprednisolone sodium succinate, fluprednisolone sodium
succinate, and dexamethasone sodium phosphate.
3. The method of claim 1 wherein the prostaglandin is administered
in a dosage of from about 0.1 mcg. to about 25 mcg./kg.
4. The method of claim 1 wherein the prostaglandin is
PGF.sub.2.sub..alpha..
5. The method of claim 1 wherein the mammal is a human.
6. The method of claim 1 wherein the mammal is a valuable warm
blooded domestic animal.
7. The method of claim 1 wherein the administration is
intravenous.
8. The method of claim 7 wherein the nontoxic effective amount is
within the range of 0.1 mcg. to 25 mcg. per kilo per minute.
Description
BACKGROUND OF THE INVENTION
Since the early work of von Euler wherein "Prostaglandin" referred
to a fraction of human semen containing lipid-soluble acids,
continued research and development have followed in this area of
substances related to prostanoic acid. The latter is represented
structurally as ##SPC1##
A systematic name for prostanoic acid is
7-[(2.beta.-octyl)cyclopent-1.alpha.-yl]heptanoic acid. Isolation
and purification of naturally occurring prostaglandins have
continued as have preparation of derivatives and biological
studies.
Among the known prostaglandins are those referred to as A-type
prostaglandins. E-type prostaglandins and F-type prostaglandins by
those of skill in the relevant art. Ramwell et al.,
"Prostaglandins" in Progress in the Chemistry of Fats and Other
Lipids, Vol. 9, R. Holman Editor, pp. 231-273, Pergamon Press,
Oxford, 1968, and references cited therein present a detailed
description of preparation methods and nomenclature. Among others
U.S. Pat. Nos. 3,069,322; 3,296,091; and British specification No.
1,040,544 describe the prostaglandins. The A-type prostaglandins
characterized by a double bond between carbon atoms 10 and 11 in
the cyclopentane ring include prostaglandin A.sub.1 or PGA.sub.1,
prostaglandin A.sub.2 or PGA.sub.2, prostaglandin A.sub.3 or
PGA.sub.3, and dihydro prostaglandin A.sub.1 or dihydro PGA.sub.1.
Similarly, the E-type prostaglandins with a keto group at the 9
position include PGE.sub.1, PGE.sub.2, PGE.sub.3, and dihydro
PGE.sub.1, while the F-type prostaglandins with a hydroxyl at the 9
position include PGF.sub.1.sub..alpha., PGF.sub.2.sub..alpha. ,
PGF.sub.3.sub..alpha. and dihydro PGF.sub.1.sub..alpha.. The
.alpha.-designation shows the configuration of the hydroxyl group
at the 9 position in the cyclopentane ring.
Pharmaceutically acceptable salts for example, those of alkali
metals and alkaline earth bases, such as the sodium, potassium,
calcium and magnesium salts; those of ammonia or a basic amine such
as mono-, di-, and triethylamines, benzylamine, heterocyclic amines
such as piperidine and morpholine, and amines containing water
solubilizing or hydrophilic groups such as triethanolamine,
tris(hydroxymethyl)aminomethane, and phenylmonoethanoethanolamine
are described in U.S. Pat. No. 3,069,322 and British Pat. No.
1,040,544.
The several prostaglandins are to be construed herein as including
optically active compounds of the natural configuration and racemic
compounds. All of these compounds, including the free acids and
salts, are known in the art or can be prepared by known methods.
See, for example, U.S. Pat. No. 3,296,091; Belgian Pat. Nos.
736,728 and 747,348; Rec. Trav. Chem. 85, 1233 (1966); ibid. 87,
461 (1968); J. Am. Chem. Soc. 90, 5895 (1968); ibid 91, 5364
(1969); ibid. 91, 5373 (1969); Chem. Communications, 302 (1969);
ibid. 602 (1970). The PGF.sub..alpha.-type compounds are also
prepared by carbonyl reduction of the corresponding PGE-type
compounds, advantageously with sodium borohydride according to
known procedures. When an active ingredient is named hereinafter,
for example, PGE.sub.2 or PGF.sub.2.sub..alpha., the optically
active form with the natural configuration is intended. When
reference is made to racemic ingredients, the designation racemic
or dl is used.
Biological studies of the prostaglandins, for example, actions on
smooth muscle, reproductive systems, nervous systems,
cardiovascular system, and relationship to lipid and carbohydrate
metabolism, and miscellaneous effects are summarized by Bergstrom
et al. "The Prostaglandins: A Family of Biologically Active
Lipids," Pharmacological Reviews, Vol. 20, No. 1, p. 1 et sequitur,
March, 1968, the Williams and Wilkins Company, and references cited
therein. Further biological studies include the effect of
PGF.sub.2.sub..alpha. on isolated strips of human pregnant and
non-pregnant myomatrium in vitro. Bygdeman (1964) Acta. Physiol.
Scand. 63, (suppl. 242), 1; Pickles and Hall (1963) J. Reprod.
Fert. 6, 315 and Sandberg et al. (1965) Acta. Obstet, Gynec. Scand,
44, 585. Also Karim, S.M.M. (1966) J. Obstet, Gynaec. Brit. Cwlth.
73, 903 and Karim and Devlin (1967) ibid, 230 have shown that
PGF.sub.2.sub..alpha. is present in human amniotic fluid obtained
during labor. Wiqvist et al., Am. J. Obstet, Gyn. 102, 327-332
(1968) studied the effect of prostaglandin E.sub.1 on the
midpregnant human uterus. They observed that intra-amniotic or
vaginal administration of PGE.sub.1 in high doses had no effect on
the uterus. Further, Karim, British Med. J. 4, 618 (1968) has shown
that PGF.sub.2.sub..alpha. appears in the maternal venous blood in
variable amounts during labor. It is against this background that
the present invention has been conceived and embodied.
BRIEF SUMMARY OF THE INVENTION
This invention relates to a process of treatment, more particularly
a process of utilizing certain prostaglandins in effective
non-toxic amounts in the clinical management of shock wherein acute
peripheral circulatory failure occurs.
DETAILED DESCRIPTION
The clinical condition known as shock is marked by pallor and
clamminess of the skin, decreased blood pressure, feeble rapid
pulse, decreased respiration, restlessness, anxiety, and sometimes
unconsciousness. It is familarly known to follow injury and trauma.
However, it manifests itself from other etiology and may be
denominated hemorrhagic shock, cardiogenic shock as a sequel to
surgical procedures, and endotoxic shock as from generalized
systematic infection or the like. Heroic emergency measures are
required to successfully manage such shock conditions and the
search for beneficial methods and medications continues without
cease. It has now been found according to the present invention
that certain known prostaglandins suitably combined with
pharmaceutical means which adapt the combination for parenteral
administration are unexpectedly beneficial in shock, especially the
early stages thereof. Apparently the combinations maintain adequate
blood perfusion of the vital organs. In contrast to other agents,
for example phenoxybenzamine, the prostaglandin does not lower
systemic blood pressure, but unexpectedly exerts a pressor response
by causing constriction of the veins. Irreversible shock involving
profound fall in blood pressure, dilation of veins and venous
pooling is prevented.
Generally, the prostaglandin is administered parenterally at a dose
of from about 0.1 mcg. to about 25 mcg./kg. per minute. For ease of
preparation of an I.V. infusion solution, a prostaglandin acid is
dissolved in ethanol and diluted with physiological saline to reach
a final concentration of about 100 mcg./ml. in 10% ethanol. Other
intraveneously acceptable vehicles can be utilized, for example,
water containing one equivalent of sodium bicarbonate; or
carbonate. Aqueous solutions containing ethanol, propylene glycol,
a polyethylene glycol or dimethylacetamide are useful in
embodiments in the form of aqueous preparations for subcutaneous or
intramuscular administration according to the inventive concept.
The pharmaceutically acceptable salts are especially useful in
solution form. Other forms of the prostaglandins are prepared as
solutions or suspensions depending on the concentration per unit
volume. Hence, the prostaglandin is prepared in a pharmaceutical
form, and as exemplified for those skilled in the art said form
supplies an effective nontoxic amount for combating shock by venous
constriction.
Other known compounds can be used as advantageous supplements to
the prostaglandin in dosages known to the art, for example,
norepinephrine, dopamine, phenoxybenzamine hydrochloride,
phentolamine hydrochloride, chlorpromazine hydrochloride,
promethazine hydrochloride, hydrocortisone 21-sodium succinate,
methylprednisolone 21-sodium succinate, and fluprednisolone sodium
succinate, dexamethasone sodium phosphate, and like steroid
compounds.
Unexpectedly, supplementing the prostaglandin with these agents
counteracts the undesirable venodilatation caused by these agents
but does not counteract the desirable arteriolar dilation which is
important for the maintenance of adequate blood perfusion of the
vital tissues.
In effectively combating traumatic shock, for example, replacement
of lost body fluid is immediately done by intravenous drip, for
example dextrose-saline solution. Shortly thereafter a solution of
the prostaglandin in about 10% ethanol is infused at the rate of 1
to 25 mcg./kg. per minute into the existing intravenous cannula. If
desired, approximately 10 minutes later an additional intravenous
infusion of one of the supplementary compounds is begun.
Advantageously, a decrease in the amount of fluid required for
replacement results because a reduction occurs in the size of the
venous side of the circulation.
The following examples describe the manner and process of using the
invention and set forth for the best mode contemplated by the
inventor of carrying out his invention but are not to be construed
as limiting.
EXAMPLE 1
Experimental dogs (12-20 kg.) are prepared with a right ventricular
by-pass so that venous blood is routed through a pump providing a
constant flow to lungs. Also, a venous stabilization reservoir is
placed between the right auricle and the pump to measure changes in
the volume of blood flowing to the auricle as an index of
venoconstriction. The results obtained from 16 animals subjected to
this procedure are shown in the following table.
Table
__________________________________________________________________________
Effect of Epinephrine and Prostaglandin F.sub.2a on Blood Pressure,
Pulmonary Perfusion Pressure, and Reservoir Volume Epinephrine
Prostaglandin F.sub.2
__________________________________________________________________________
Dose .DELTA.MAP .DELTA.PPP .DELTA.Res V Dose .DELTA.MAP .DELTA.PPP
RES V .mu.g/kg (mm Hg) (mm Hg) (cc) .mu.g/kg (mm Hg) (mm Hg) (cc)
__________________________________________________________________________
1 +28 +3.5 +18 10 +20 +16 +30 1 +20 +4 +10 10 0 +19 +40 1 +16 +4
+18 10 0 +19 +56 1 +20 +1.5 +32 1 +13 +13 + 8 0.5 +16 0 +47 10 0
+28 +14 0.5 +24 +3 +52 10 + 8 +13.5 0 1 +10 0 +10 10 0 +10 +45 0.5
+20 +0.5 +33 10 +18 +16 +58 0.5 +18 +2 +56 10 +16 + 15 +43 0.5 +17
+1 +39 10 +12 +29 +18 0.5 +24 +2 +34 10 +18 +17 +56 0.5 +11 +2 +44
10 0 +13 0 0.5 +22 +2 +18 10 + 7 +33 0 0.5 +16 +1 +10 10 +10 +10
+78 0.5 +22 -10 +64 10 0 +22 +92 0.5 +16 0 +32 10 - 4 +16 +46
Average* 18.72 1.22 39 7 16.75 38.4
__________________________________________________________________________
*Averages of only 0.5 .mu.g/kg doses of epinephrine and 10 .mu.g/kg
doses of PCF.sub.2c ; .DELTA.MAP = change in mean arterial
pressure; .DELTA. PP = change in pulmonary perfusion pressure;
.DELTA. Res V = change in reservoir volume.
Prostaglandin F.sub.2.sub..alpha. at a dose of 10 .mu.g. and
epinephrine at 0.5 .mu.g./kg. were found to have approximately
equivalent effects on vascular capacity as indicated by the
accumulation of blood within the reservoir. It is important to
note, however, that this dose of PGF.sub.2.sub..alpha. caused only
a 7 mm. Hg increase in mean arterial pressure, whereas epinephrine
caused a 19 mm. Hg increase. Therefore the results of this study
indicate that the activity of PGF.sub.2.sub..alpha. was primarily
on the venous side of the circulatory system. Blood accumulating in
the reservoir reflects a change in venous capacity rather than
arterial capacity, since epinephrine elevated the arterial blood
pressure more than twice as much as did PGF.sub.2.sub..alpha. and
yet caused approximately the same amount of blood loss. Additional
evidence in support of this conclusion was obtained from six
animals which were given 0.5 .mu.g/kg. of norepinephrine. In these
animals the average increase in mean arterial pressure was about
the same as that seen with epinephrine (21.2 mm. Hg compared to
18.7 mm. Hg), but the amount of blood accumulating in the reservoir
was much less (10.2 cc. compared to 39 cc.). Therefore, the
experimental evidence supports the conclusion that a change in the
volume of blood contained within the reservoir reflects a change in
the capacity of the venous rather than the arterial
vasculature.
EXAMPLE 2
Upon entering the hospital emergency service a victim of an
automobile accident is disgnosed as being in shock caused by both
trauma and hemorrhage. Replacement of lost body fluid is
immediately begun by intravenous drip. Shortly thereafter, a
solution of 100 ug/ml. of PGF.sub.2.sub..alpha. in 10% ethanol is
infused at a rate of 1-5 .mu.g/kg./minute into the existing
intravenous cannula. Approximately 10 minutes later an additional
intravenous infusion of 1 mg./kg. of phenoxybenzamine diluted in
250 to 500 ml. of 5% glucose or 0.9% sodium chloride is begun, also
into the existing intravenous cannula, and continued over the
course of at least one hour. The infusion of PGF.sub.2.sub..alpha.
is continued until the patient shows signs of emerging from the
shock syndrome.
EXAMPLE 3
Subsequent to major surgery a patient falls into the early stages
of shock, showing a mean arterial pressure of about 60 mm. of
mercury.
Immediate supportive measures are instituted involving the infusion
of dihydro-PGF.sub.1.sub..alpha. at a rate of about 20
mcg./kg./minute. Within about 20 minutes the clinical signs
indicate beginning recovery and subsequently there is continued
recovery with a mean arterial pressure of about 90 mm. of mercury
after about 4 hours.
EXAMPLE 4
Similar results are obtained in shock, especially the early stages
thereof, utilizing the pharmaceutically acceptable salts of the
prostaglandins.
Phenoxybenzamine hydrochloride is used as a supplementary treatment
at a dosage of 1 mg./kg. in the form of a dilution in about 500 ml.
of 5% glucose or 0.9% sodium chloride. Infusion is continued
intraveneously for about 1 hour.
EXAMPLE 5
An injured dog is found to be in shock with a mean blood pressure
of about 50 mm. of mercury in contrast to the normal mean pressure
of about 100 mm.
Infusion of PGF.sub.1.sub..alpha. at a dosage of 10 mcg./kg./minute
is started. Within about 15 minutes the mean pressure rises to
about 80 mm. and thereafter slowly rises to about 100 mm.,
indicating recovery from the shock syndrome.
EXAMPLE 6
Supplementing treatment of shock by infusion of the patient with a
solution of prostaglandin PGF.sub.3.sub..alpha. as described above,
methylprednisolone sodium succinate is infused at a dosage of 30
mg. given over about 5 minutes. Return to normal mean arterial
pressure is achieved in about 3 hours.
EXAMPLE 7
For intramuscular administration a sterile suspension of PGA.sub.1
in water is prepared at a concentration of 1.5 mg. per milliliter.
One milliliter is administered intramuscularly to a human weighing
about 70 kilo as an emergency measure in combating shock prior to
hospitalization. Successful results are obtained.
EXAMPLE 8
PGE.sub.2 is beneficially administered subcutaneously at a dosage
of 15 mcg. per kilo to a human suffering from the preliminary stage
of traumatic shock. Thereafter hospitalization and intravenous
administration are followed by recovery.
EXAMPLE 9
The tris(hydroxymethyl)aminomethane salt of PGE.sub.3 is
administered as an aqueous solution intravenously at a rate of 10
mcg. per minute per kilogram to a human suffering from endotoxic
shock. Administration continued for about 15 minutes is followed by
increasing blood pressure with continued recovery after about 3
hours.
EXAMPLE 10
Equally beneficial results are obtained with the other A-type,
X-type and F-type prostaglandins by suitable intravenous,
intramuscular and subcutaneous administration in shock conditions
in humans and warm blooded animals.
* * * * *